- cafead May 23, 2024 at 11:02: AM
via Sanofi has announced positive outcomes from a Phase II clinical trial of rilzabrutinib, an oral treatment for adults with uncontrolled moderate-to-severe asthma.
The double-blind, randomised, placebo-controlled, parallel-group trial analysed the safety, tolerability and efficacy of rilzabrutinib over 12 weeks.
article source
The double-blind, randomised, placebo-controlled, parallel-group trial analysed the safety, tolerability and efficacy of rilzabrutinib over 12 weeks.
article source